Literature DB >> 17459080

Salmonella typhimurium stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model.

D A Shilling1, M J Smith, R Tyther, D Sheehan, K England, E G Kavanagh, H P Redmond, F Shanahan, L O'Mahony.   

Abstract

Appropriate activation of the immune system and effective targeting of tumour cells are the primary hurdles to be overcome for cancer immunotherapy to be successful and applicable to a wide range of tumour types. Our studies have examined the ability of bacterial-stimulated dendritic cells (DCs), loaded with tumour-associated antigens, to inhibit tumour growth in a murine model. Immature murine bone marrow-derived DCs were stimulated in vitro with the cytoplasmic fraction (CM) of Salmonella typhimurium in combination with heat shock proteins (hsps) from 4T1 tumours, isolated using heparin affinity chromatography. Activated DCs were administered subcutaneously. Tumours were generated by orthotopic inoculation of 4T1 cells in Balb/c mice. Primary tumour growth was measured using Vernier calipers, while lung metastases were measured using the clonogenic assay. S. typhimurium CM induced potent tumour necrosis factor (TNF)-alpha responses from DCs accompanied by significant up-regulation of CD80 and CD86 expression. When injected into mice, bacterial-stimulated DCs loaded with 4T1 hsps inhibited the formation of new 4T1 tumours and reduced the growth rate of established tumours. In addition, the number of lung metastatic nodules was reduced significantly in the DC-treated mice (1.6 +/- 0.6 versus 245.9 +/- 55.6, P = 0.0015). DCs stimulated with CM alone, exposed to tumour hsps alone or exposed to tumour hsps from an unrelated tumour cell line did not induce a protective immune response. Dendritic cells primed with a proinflammatory bacterial stimulus and tumour-associated antigens induce a protective anti-tumour immune response in this murine model.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459080      PMCID: PMC1942028          DOI: 10.1111/j.1365-2249.2007.03393.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Tumor vaccination by Salmonella typhimurium after transformation with a eukaryotic expression vector in mice: impact of a Salmonella typhimurium gene interfering with MHC class I presentation.

Authors:  Susanne Hummel; Ron N Apte; Udi Qimron; Mario Vitacolonna; Angel Porgador; Margot Zöller
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

Review 2.  Breaking tolerance to tumors with dendritic cell-based immunotherapy.

Authors:  Ines Mende; Edgar G Engleman
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

3.  Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity.

Authors:  Björn Cochlovius; Marike J J G Stassar; Marco W Schreurs; Axel Benner; Gosse J Adema
Journal:  Immunol Lett       Date:  2002-02-01       Impact factor: 3.685

4.  Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.

Authors:  Fumiaki Tanaka; Hiroshi Yamaguchi; Naotsugu Haraguchi; Kohjiro Mashino; Mitsuhiko Ohta; Hiroshi Inoue; Masaki Mori
Journal:  Int J Oncol       Date:  2006-11       Impact factor: 5.650

Review 5.  Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.

Authors:  Suyu Shu; Alistair J Cochran; Rong-Rong Huang; Donald L Morton; Holden T Maecker
Journal:  Cancer Metastasis Rev       Date:  2006-06       Impact factor: 9.264

Review 6.  Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity.

Authors:  R Kim; M Emi; K Tanabe
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

7.  Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination.

Authors:  R Weth; O Christ; S Stevanovic; M Zöller
Journal:  Cancer Gene Ther       Date:  2001-08       Impact factor: 5.987

Review 8.  Natural killer-dendritic cell cross-talk in cancer immunotherapy.

Authors:  Pawel Kalinski; Robbie B Mailliard; Adam Giermasz; Herbert J Zeh; Per Basse; David L Bartlett; John M Kirkwood; Michael T Lotze; Ronald B Herberman
Journal:  Expert Opin Biol Ther       Date:  2005-10       Impact factor: 4.388

Review 9.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

Authors:  Giorgio Parmiani; Chiara Castelli; Piero Dalerba; Roberta Mortarini; Licia Rivoltini; Francesco M Marincola; Andrea Anichini
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

Review 10.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

View more
  5 in total

Review 1.  Engineering the perfect (bacterial) cancer therapy.

Authors:  Neil S Forbes
Journal:  Nat Rev Cancer       Date:  2010-10-14       Impact factor: 60.716

2.  Combined Extract of Heated 4T1 and a Heat-Killed Preparation of Lactobacillus Casei in a Mouse Model of Breast Cancer.

Authors:  Sajjad Jafari; Seyyed Meysam Abtahi Froushani; Amir Tokmachi
Journal:  Iran J Med Sci       Date:  2017-09

Review 3.  Salmonella-Mediated Cancer Therapy: An Innovative Therapeutic Strategy.

Authors:  Ze Mi; Zhi-Chao Feng; Cheng Li; Xiao Yang; Meng-Tian Ma; Peng-Fei Rong
Journal:  J Cancer       Date:  2019-08-20       Impact factor: 4.207

Review 4.  Recombinant Attenuated Salmonella enterica as a Delivery System of Heterologous Molecules in Cancer Therapy.

Authors:  Elayne Irene Becerra-Báez; Sergio Enrique Meza-Toledo; Paola Muñoz-López; Luis Fernando Flores-Martínez; Karla Fraga-Pérez; Kevin Jorge Magaño-Bocanegra; Uriel Juárez-Hernández; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

Review 5.  Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated Salmonella enterica.

Authors:  Marco Antonio Hernández-Luna; Rosendo Luria-Pérez
Journal:  J Immunol Res       Date:  2018-09-13       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.